Stock report · Delisted · Nasdaq
Neurobo Pharmaceuticals Inc (NRBO)
1.89USD Delisted Final close · Jan 29, 2025
NRBO no longer trades. Neurobo Pharmaceuticals was delisted from the Nasdaq in January 2025.
All prices on this page are historical. The last trade was on January 29, 2025, at $1.89.
NRBO stock price history
Final trading statistics
- Final close
- $1.89
- Final trading day
- Jan 29, 2025
- Market cap at delisting
- $16.28M
- Shares outstanding
- 8.62M
- Final 52-week range
- $1.51 – $6.75
- Avg. volume (final 3 mo.)
- 134,149
- All-time high
- $126420.00 · Jul 2017
- All-time low
- $1.60 · Dec 2024
- Return since IPO
- -100.0%
- Beta
- -0.28
- Book value / share
- $1.50
- Price / book
- 1.26
About Neurobo Pharmaceuticals Inc
NeuroBo Pharmaceuticals, renamed MetaVia Inc. in November 2024, was a clinical-stage biotechnology company developing drugs for cardiometabolic diseases. DA-1241, a GPR119 agonist that could be used alone or in combination, was in a Phase 2a trial for MASH and had finished Phase 1 for type 2 diabetes. DA-1726, a GLP-1 and glucagon receptor dual agonist, was in preclinical work for obesity.
Other programs included ANA001, an oral niclosamide for moderate COVID-19; NB-01 for painful diabetic neuropathy; NB-02 for cognitive impairment; and Gemcabene for dyslipidemia, licensed from Pfizer. It worked with Dong-A ST and ImmunoForge on DA-1726.
The company was based in Cambridge, Massachusetts. Its shares under the NRBO symbol were delisted from the Nasdaq in January 2025, with the last trade on January 29, 2025 at $1.89.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Cambridge, MA
- Employees
- 8
- IPO date
- August 5, 2016
- Delisted
- January 29, 2025
- SEC CIK
- 1638287
Neurobo Pharmaceuticals financials before the delisting
The last 5 fiscal years Neurobo Pharmaceuticals reported as a public company, fiscal year ending December.
NRBO revenue and net income
NRBO earnings per share
NRBO annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $7.0K | −$12.5M | −$2.49 |
| FY2022 | $0.00 | −$6.1M | −$5.61 |
| FY2021 | $0.00 | −$15.2M | −$51.39 |
| FY2020 | $0.00 | −$29.6M | −$55.20 |
| FY2019 | $0.00 | −$22.4M | −$263.85 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Neurobo Pharmaceuticals stock FAQ
What happened to Neurobo Pharmaceuticals stock?
Neurobo Pharmaceuticals was delisted from the Nasdaq in January 2025. The final close was $1.89 on January 29, 2025.
Can I still buy NRBO stock?
No. NRBO is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on January 29, 2025.
What was the last price of NRBO?
NRBO last closed at $1.89 on January 29, 2025, which valued the company at about $16.28M.
How did Neurobo Pharmaceuticals do in its last full fiscal year?
In fiscal 2023, its last full year as a public company, Neurobo Pharmaceuticals reported revenue of $7.0K and net income of −$12.5M.
When did Neurobo Pharmaceuticals go public?
Neurobo Pharmaceuticals shares started trading on August 5, 2016.
NRBO no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.